The Alectos pipeline is focused on creating new treatments for patients with neurological disorders, including those living with Parkinson’s and Alzheimer’s diseases. Our preclinical programs aim to identify and develop novel small molecules as potential disease-modifying therapies.
Glucocerebrosidase 2 (GBA2) inhibition has emerged as a novel therapeutic strategy to enhance lysosomal function in neurodegenerative diseases. In the Alectos GBA2 program, we have identified molecules that possess drug-like properties including good potency, selectivity, pharmacokinetics, and CNS penetrance. Our lead compound, AL01811, is a selective GBA2 inhibitor with first-in-class potential as an oral disease-modifying treatment for patients with Parkinson’s disease. This program has recently been partnered with Biogen.
Inhibition of O-GlcNAcase (OGA) is a promising approach for the treatment of several neurodegenerative diseases, including Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, and ischemic stroke. Alectos previously partnered with Merck to advance the first clinical OGA inhibitor and OGA PET ligand to phase 1 studies, where they were found to be safe and well-tolerated. Alectos has repatriated this program and we are focused on advancing a novel OGA development candidate, enabled by our OGA PET ligand to measure target engagement in the clinic. The Alectos OGA program builds on our deep knowledge and scientific leadership in this area. We welcome partnership inquiries regarding our OGA inhibitor program and our advanced preclinical development candidates.